John Thero

16 results

Irish drug company Amarin says sales from Vascepa, its one cardiovascular drug for 2019, will be at or above the upper end of its previous guidance

Irish drug company Amarin says sales from its one cardiovascular drug for 2019 will be at or above the upper end of its previous guidance – indicating(...)

Noel and Valerie Moran walked away with a €266 million payout for Prepaid Financial Service. Photograph: Alan Betson

It was a year of extremes in the corporate world – financial reward and glory for some; the end of the road for others. And 2019 also saw a cast of fi(...)

Amarin’s Vascepa has been found to reduce the risk of cardiovascular events in high-risk patients already being treated with statins.

Amarin, the US-based Irish drug development business, said the European Medicines Agency has accepted an application to licence its cardiovascular dru(...)

Amarin’s John Thero:  “Breakthroughs in preventative cardiovascular care are rare and greatly needed.” Photograph: Cyril Byrne

John Thero, the president and chief executive of fish-oil drug specialist Amarin, has been awarded the EY Entrepreneur of the Year award in the US for(...)

Vascepa is aiming to become the first prescription drug for people at risk of stroke or heart attack who continue to have high levels of harmful blood fats despite being on treatment with statins

Shares in US-listed Irish biotech Amarin surged in New York after it upgraded its profit forecasts. A strong update for the prospects of its cardiova(...)

John Thero: ‘I am pleased that Amarin’s significant progress and innovative work is recognised by this award.’ Photograph: Cyril Byrne

Fish oil drug specialist Amarin has been recognised for the breakthrough results for its one medicine, Vascepa, as a cardiovascular therapy. John The(...)

The FDA grants priority review only to drugs that have the potential to offer significant improvement in the treatment of serious conditions.

Shares in Irish drug company Amarin jumped 14 per cent after its Vascepa drug was fast-tracked for approval as a treatment for reducing the risk of he(...)

US FDA approval would allow Amarin to pitch its fish-oil drug direct to the consumer rather than solely through the medical practitioner channel. File photograph: Getty

Shareholders tuning into Amarin’s annual shareholders’ meeting in Dublin on Monday had plenty to cheer them. Shares in the company have risen more th(...)

Amarin chief executive John Thero: ‘Our guidance is for 50 per cent greater growth over the prior year’

Irish drug company Amarin will seek European approval for its cardiovascular drug Vascepa before the end of the year. The drug is in the process of s(...)

Aryzta had an unremitting bad year and was the  standout corporate loser of 2018. Photograph: Reuters

It was another year of mixed fortunes in corporate Ireland. The economy continues to be the fastest growing in Europe while the live register fell to (...)

  • 1
  • 2
  • Next
  • Last »